Abstract
In this report we will provide additional insight on the individual features of age-related causes of mobility limitation, explaining why insulin resistance, related to lower muscle functioning, sub-inflammation and hormonal changes, may contribute to its onset and sustain it. According to the recent literature, the same factors playing a role in the onset and maintenance of insulin resistance are related to mobility limitation. Thus, the presence of insulin resistance can be considered a biomarker of susceptibility to mobility limitation among older persons. All described factors related to both conditions are strictly intertwined. Therefore, the identification and correction of a single factor is difficult to convert into clinical practice. Instead, insulin resistance may be considered not only an early biological marker, but also a predictive and modifiable marker of mobility limitation. Thus, interventions aimed at correcting insulin resistance may have a potential role in preventing or at least slowing down functional decline in the elderly population, promoting a better quality of life and potentially extending the “healthspan”.
Keywords: Insulin resistance, mobility limitation, older persons.
Current Pharmaceutical Design
Title:The Link between Insulin Resistance and Mobility Limitation in Older Persons
Volume: 20 Issue: 19
Author(s): Virginia Boccardi and Giuseppe Paolisso
Affiliation:
Keywords: Insulin resistance, mobility limitation, older persons.
Abstract: In this report we will provide additional insight on the individual features of age-related causes of mobility limitation, explaining why insulin resistance, related to lower muscle functioning, sub-inflammation and hormonal changes, may contribute to its onset and sustain it. According to the recent literature, the same factors playing a role in the onset and maintenance of insulin resistance are related to mobility limitation. Thus, the presence of insulin resistance can be considered a biomarker of susceptibility to mobility limitation among older persons. All described factors related to both conditions are strictly intertwined. Therefore, the identification and correction of a single factor is difficult to convert into clinical practice. Instead, insulin resistance may be considered not only an early biological marker, but also a predictive and modifiable marker of mobility limitation. Thus, interventions aimed at correcting insulin resistance may have a potential role in preventing or at least slowing down functional decline in the elderly population, promoting a better quality of life and potentially extending the “healthspan”.
Export Options
About this article
Cite this article as:
Boccardi Virginia and Paolisso Giuseppe, The Link between Insulin Resistance and Mobility Limitation in Older Persons, Current Pharmaceutical Design 2014; 20(19) . https://dx.doi.org/10.2174/13816128113196660683
DOI https://dx.doi.org/10.2174/13816128113196660683 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Aβ1-40 and Aβ1-42 Plasmatic Levels In Stroke: Influence of Pre-Existing Cognitive Status and Stroke Characteristics#
Current Alzheimer Research Relationship Between Cigarette Smoking and Other Coronary Risk Factors in Atherosclerosis: Risk of Cardiovascular Disease and Preventive Measures
Current Pharmaceutical Design Diagnosis and Management of Hypertensive Emergencies Complicating Pregnancy
Current Women`s Health Reviews Oxidative Stress Signaling in Alzheimers Disease
Current Alzheimer Research subject Index To Volume 4
Combinatorial Chemistry & High Throughput Screening The Effects of Incretins on Energy Homeostasis: Physiology and Implications for the Treatment of Type 2 Diabetes Mellitus and Obesity
Current Vascular Pharmacology Coronary Pressure Measurement Based Decision Making for Percutaneous Coronary Intervention
Current Cardiology Reviews Metabolic Syndrome and Cardiometabolic Risk Factors
Current Vascular Pharmacology Transcriptional Regulation of the Heme Oxygenase-1 Gene Via the Stress Response Element Pathway
Current Pharmaceutical Design CD31+ Circulating Angiogenic Cell Number and Subtypes are Reduced in Individuals with Chronic Stroke
Current Neurovascular Research Stabilization of Folding Intermediate States from Alkaline Induced Unfolded State of Bovine Serum Fetuin in Trifluoroethanol and Acetonitrile
Protein & Peptide Letters Exercise and Postprandial Glycemic Control in Type 2 Diabetes
Current Diabetes Reviews ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery In Silico Bioactivity Prediction of Methoxime-3,4-dephostatin Derivatives on Human PTP1B: Search for Novel Antidiabetic Leads
Letters in Drug Design & Discovery The Research Progress of DPP-4 Inhibitors
Mini-Reviews in Medicinal Chemistry Efficacy of Direct-Acting Antiviral Combination Therapy in the Treatment of Hepatitis C Virus Among Kidney Transplant Patients
Anti-Infective Agents Hypertension in Older Patients
Current Hypertension Reviews Hypertension in Peripheral Arterial Disease
Current Pharmaceutical Design Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
Current Pharmaceutical Design